Neurosense Therapeutics Ltd (NRSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has a cash flow conversion efficiency ratio of 1.177x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.84 Million) by net assets ($-1.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Neurosense Therapeutics Ltd to measure how much of total assets are equity-financed.
Neurosense Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Neurosense Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neurosense Therapeutics Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Neurosense Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voyageur Pharmaceuticals Ltd
V:VM
|
-0.295x |
|
Initiator Pharma A/S
ST:INIT
|
-0.144x |
|
AlphaVest Acquisition Corp Ordinary Shares
NASDAQ:ATMV
|
0.004x |
|
Hui Srl
VI:HUI
|
N/A |
|
Zhonglu Co Ltd B
SHG:900915
|
0.056x |
|
Artego Tg. Jiu
RO:ARTE
|
N/A |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
0.019x |
|
Millennium Group International Holdings Limited Ordinary Shares
NASDAQ:MGIH
|
-0.051x |
Annual Cash Flow Conversion Efficiency for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neurosense Therapeutics Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Neurosense Therapeutics Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.56 Million | $-7.67 Million | 4.917x | +225.32% |
| 2024-12-31 | $2.58 Million | $-10.13 Million | -3.924x | -182.62% |
| 2023-12-31 | $-1.76 Million | $-8.35 Million | 4.749x | +451.78% |
| 2022-12-31 | $5.62 Million | $-7.59 Million | -1.350x | -690.04% |
| 2021-12-31 | $9.01 Million | $-1.54 Million | -0.171x | +83.80% |
| 2020-12-31 | $659.00K | $-695.00K | -1.055x | -66.35% |
| 2019-12-31 | $918.00K | $-582.00K | -0.634x | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more